Get the Daily Brief

All action, no filler. BioBriefs delivers the industry’s 10 must-know updates, every morning.

Latest Biotech News

Novo Nordisk Foundation pledges up to $850M to scale European biotech

January 17, 2026

The Novo Nordisk Foundation committed up to $850 million to expand the BioInnovation Institute’s support for startups across Europe, moving the Danish‑born innovation engine into a continental...

Conference cash flow: JPM lifts biotech financings and deal activity

January 17, 2026

Industry trackers reported a notable uptick in biotech financings and deal volume during JP Morgan week, with BioCentury flagging increased capital commitments and Q4 2025 closing the year with a...

Vedanta cuts staff to prioritize phase‑3 VE303 for C. difficile

January 17, 2026

Vedanta Biosciences said it significantly reduced its workforce and refocused resources on advancing VE303, an eight‑strain live bacterial consortium in Phase 3 for prevention of recurrent...

HHS greenlights controversial newborn hepatitis B trial in Africa — ethics debate continues

January 17, 2026

The U.S. Department of Health and Human Services confirmed a planned randomized study in Guinea‑Bissau that will investigate health effects of neonatal hepatitis B vaccination, despite ethical...

ImmunityBio’s off‑the‑shelf CAR‑NK: durable complete responses in Waldenström’s

January 17, 2026

ImmunityBio reported early clinical activity for its allogeneic CD19 CAR‑NK therapy in patients with Waldenström’s macroglobulinemia. Company data show durable complete responses in the first four...

Tecvayli tops standard regimens – J&J cites survival gains in earlier multiple myeloma

January 17, 2026

Johnson & Johnson disclosed Phase 3 results showing Tecvayli (a bispecific antibody) reduced the risk of progression or death by 71% versus standard regimens in earlier‑line multiple myeloma...

UC San Diego wins ARPA‑H grant: $25.8M to 3D‑print patient‑specific livers

January 17, 2026

UC San Diego secured up to $25,771,771 from ARPA‑H to develop a patient‑specific, 3D‑bioprinted human liver under the agency’s PRINT program. The five‑year award funds multidisciplinary work to...

MRD moves: BloodPAC issues validation protocols as Veracyte primes TrueMRD launch

January 17, 2026

BloodPAC published generic analytical validation protocols for tumor‑informed circulating tumor DNA (ctDNA) assays to harmonize MRD (minimal residual disease) testing standards across platforms....

Novo Nordisk Foundation pledges up to $850M to seed European life‑science startups

January 17, 2026

The Novo Nordisk Foundation committed up to $850 million to expand the BioInnovation Institute’s reach across Europe, the foundation said. The funding will scale startup support services that the...

White House pushes ‘Great Healthcare Plan’ — drug‑pricing fight shifts to Congress

January 17, 2026

The administration unveiled the Great Healthcare Plan promising lower drug costs and direct payments to ACA enrollees, but industry executives told reporters the policy lacks operational detail....

Vedanta trims workforce to concentrate resources on VE303 phase‑3 for C. difficile

January 17, 2026

Vedanta Biosciences confirmed a significant headcount reduction to preserve capital and focus on advancing VE303, its eight‑strain live bacterial consortium for preventing recurrent Clostridioides...

FDA grants RMAT to iRegene’s NouvNeu001 — regulatory double‑play for iPSC Parkinson’s therapy

January 17, 2026

iRegene Therapeutics announced the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to NouvNeu001, its chemically induced allogeneic iPSC‑derived cell therapy for...

Cellares inks long‑term lease in Leiden to expand automated cell‑therapy manufacturing network

January 17, 2026

Cellares signed a long‑term lease for a Smart Factory facility at Leiden Bio Science Park to establish a European hub for automated cell‑therapy development and manufacturing. The...

Agenus seals $141M collaboration with Zydus to accelerate BOT+BAL immunotherapy and US manufacturing

January 17, 2026

Agenus closed a previously announced $141 million strategic collaboration with Zydus Lifesciences to advance the botensilimab plus balstilimab (BOT+BAL) immunotherapy program. The deal secures...

ImmunityBio CAR‑NK posts durable complete responses

January 17, 2026

ImmunityBio reported early clinical activity from its off‑the‑shelf CD19 CAR‑NK program in Waldenström’s macroglobulinemia, with patients achieving durable complete responses without...

ARPA‑H backs 3D‑printed livers: UC San Diego lands major grant

January 17, 2026

UC San Diego secured an ARPA‑H Personalized Regenerative Immunocompetent Nanotechnology Tissue (PRINT) award to develop patient‑specific, 3D‑bioprinted human livers, receiving up to $25.77 million...

Boston Scientific goes all‑in: $14.5B bid for Penumbra

January 17, 2026

Boston Scientific announced a cash‑and‑stock agreement to acquire Penumbra for about $14.5 billion, moving to expand its footprint in thrombectomy, embolization and other interventional vascular...

Tecvayli shows survival gains in earlier multiple myeloma – J&J

January 17, 2026

Johnson & Johnson reported positive Phase 3 trial results showing Tecvayli reduced the risk of progression or death by 71% in patients with relapsed multiple myeloma compared with standard...

MRD testing: BloodPAC issues standards as labs roll out assays

January 17, 2026

BloodPAC published generic analytical validation protocols for tumor‑informed circulating tumor DNA (ctDNA) MRD assays to harmonize limit‑of‑detection, accuracy, precision and robustness testing...

Novo Nordisk Foundation commits big to scale Danish biotech innovation

January 17, 2026

The Novo Nordisk Foundation pledged up to DKK 5.5 billion (about €736 million) to expand the BioInnovation Institute (BII), scaling its support from Danish startups to a Europe‑wide innovation...